证券代码：300255 证券简称：常山药业 公告编号：2026-9 河北常山生化药业股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 河北常山生化药业股份有限公司（以下简称公司）于 2025 年 5 月 19 日召开 的 2024 年度股东大会审议并通过《关于提供担保额度预计的议案》，同意公司为 全资子公司河北常山凯库得生物技术有限公司（以下简称凯库得）借款融资提供 不超过 3.6 亿元的担保额度，上述额度期限自股东大会审议通过之日起至 2025 年度股东大会之日。具体内容详见公司刊登于巨潮资讯网的《关于提供担保额度 预计的公告》（公告编号：2025-14）。 二、担保进展 2026 年 3 月 26 日，公司与中国光大银行股份有限公司石家庄分行（以下简 称光大银行）签订了《最高额保证合同》，公司为凯库得与光大银行签订的编号 为光石综授字 20260187 号《综合授信协议》提供最高额连带责任保证担保，担 保金额为人民币 1,000 万元。 2026 年 3 月 27 日，公司与中国农业银行股份 ...

证券代码：300255 证券简称：常山药业 公告编号：2026-8 河北常山生化药业股份有限公司 关于依诺肝素钠注射液获得塔吉克斯坦药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 药品生产企业：河北常山生化药业股份有限公司 有效期：5 年 二、药品的其他相关情况 依诺肝素钠注射液用于预防静脉血栓栓塞性疾病（预防静脉内血栓形成），特 别是与骨科或普外手术有关的血栓形成；治疗已形成的深静脉栓塞，伴或不伴有 肺栓塞，临床症状不严重，不包括需要外科手术或溶栓剂治疗的肺栓塞；与阿司 匹林合用，治疗不稳定性心绞痛及非 Q 波心肌梗死；用于血液透析体外循环中， 防止血栓形成。 三、对公司的影响及风险提示 河北常山生化药业股份有限公司（以下简称公司）于近日收到通知，公司药 品依诺肝素钠注射液获得塔吉克斯坦药品监督管理部门签发的药品注册证书，现 将相关情况公告如下： 一、注册药品的基本情况 药品名称：依诺肝素钠注射液 剂型：注射剂 规格：0.4mL、0.6mL 本次依诺肝素钠注射液获得塔吉克斯坦注册批文，对公司拓展海外市场带来 一定积极影响。目前公司肝素制剂 ...

证券代码：300255 证券简称：常山药业 公告编号：2026-7 河北常山生化药业股份有限公司 关于为公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 河北常山生化药业股份有限公司（以下简称公司、母公司）于 2025 年 5 月 19 日召开的 2024 年度股东大会审议并通过《关于提供担保额度预计的议案》， 同意全资子公司河北常山凯库得生物技术有限公司（以下简称凯库得）为母公司 借款融资提供不超过 6.4 亿元的担保额度，上述额度期限自股东大会审议通过之 日起至 2025 年度股东大会之日。具体内容详见公司刊登于巨潮资讯网的《关于 提供担保额度预计的公告》（公告编号：2025-14）。 二、担保进展 2026 年 3 月 5 日，凯库得与渤海银行股份有限公司天津分行（以下简称渤 海银行）签订了《最高额保证协议》，凯库得为公司与渤海银行在一定期限内发 生的债务提供债权本金最高额不超过人民币 2 亿元整的连带责任保证。 本次担保事项在已经审议的年度担保额度范围内，无需再提交公司董事会或 股东大会审议。 三、被担保人基本情 ...

Group 1 - The core point of the article is that Changshan Pharmaceutical reported its shareholder count as of February 13, 2026, which stands at 45,332 households [2]

证券日报网讯 2月26日，常山药业在互动平台回答投资者提问时表示，二级市场股价波动受多种因素影 响，公司将持续努力提升经营质量，持续推进创新药审评工作，提升公司的内在价值。 （文章来源：证券日报） ...

Core Viewpoint - The company is actively working on the sales of Enoxaparin Sodium Injection in the U.S. market, but faces significant uncertainties due to various external factors [2] Group 1: Company Developments - The company is conducting sales-related activities for Enoxaparin Sodium Injection in the U.S. market [2] - The future sales performance of Enoxaparin Sodium Injection in the U.S. is subject to considerable uncertainty due to factors such as changes in overseas market policies, sales channels, exchange rate fluctuations, and market competition [2] - The company will announce any significant progress regarding the transfer of shareholder agreement shares in accordance with relevant regulations [2] Group 2: Regulatory Status - The application for the listing of Abepanelat is still under review, and further developments will be based on publicly available information [2]

Group 1 - RuiLian New Materials reported a total operating revenue of 1.677 billion yuan for 2025, an increase of 14.95% year-on-year, with a net profit of 311 million yuan, up 23.48% year-on-year [1] - China Shenhua's subsidiary, Guoneng Qingyuan Power, successfully put its fourth generator unit into commercial operation, expected to provide approximately 20 billion kWh of clean energy annually [2] - Qijiang Airlines announced a 6.04% year-on-year decline in passenger turnover for January 2026, with a passenger load factor of 84.03%, up 1.61% year-on-year [3] Group 2 - QiZheng Tibetan Medicine reported a total operating revenue of 2.416 billion yuan for 2025, a year-on-year increase of 3.34%, with a net profit of 646 million yuan, up 10.98% year-on-year [5] - QiaoYin Co. announced the termination of its artificial intelligence industry headquarters project due to changes in investment cooperation conditions [6] - New Point Software plans to use 90.81 million yuan of surplus raised funds for new projects, including AI-driven software development [7] Group 3 - High Measurement Co. announced plans for major shareholders and executives to reduce their holdings by up to 3.19% of the company's shares [8] - SAIC Group's subsidiary plans to establish a private equity fund with an initial scale of 2.5 billion yuan, focusing on solid-state batteries and chip localization [9] - Tianqi Lithium announced the resignation of its deputy general manager due to personal career planning [10] Group 4 - ZhongKong Technology reported a total operating revenue of 8.051 billion yuan for 2025, a decrease of 11.90%, with a net profit of 450 million yuan, down 59.70% year-on-year [11] - Spring Airlines reported a 6.28% year-on-year increase in total passenger volume for January 2026, with a total available ton-kilometers of 57,008.37 [12] - Qifan Cable's controlling shareholder reduced its stake by 3% through various trading methods [13] Group 5 - China Chemical signed contracts worth a total of 36.925 billion yuan in January 2026, with significant contracts exceeding 5 billion yuan totaling 11.371 billion yuan [19] - SaiTuo Bio received a CEP certificate for its raw material drug Betamethasone, which is used to treat allergies and autoimmune inflammation [20] - Giant Star Agriculture reported a sales revenue of 649 million yuan from commodity fat pigs in January 2026, with a sales volume of 404,400 pigs [23] Group 6 - Qinglong Pipe Industry's subsidiary won a 146 million yuan pipeline project [24] - Changshan Pharmaceutical announced that some of its products are expected to be selected for national centralized procurement [26] - Yangdian Technology completed the transfer of 12.96% of its shares through an agreement [27] Group 7 - Deepin Technology's investment fund introduced new limited partners and adjusted the capital contributions of some partners [28] - Qingyun Technology plans to pledge 25% of its shares for a loan application of up to 30 million yuan [29] - LaiMei Pharmaceutical reported a 57.20% year-on-year decline in net profit for 2025 [30] Group 8 - YouLiDe reported a 16.88% year-on-year decline in net profit for 2025, with total operating revenue of 1.221 billion yuan, up 7.99% [31] - Warner Pharmaceutical reported a net profit of 241 million yuan for 2025, an increase of 46.95% year-on-year [32] - LianRui New Materials reported a net profit of 293 million yuan for 2025, an increase of 16.42% year-on-year [33] Group 9 - HuaQin Technology expects a 24.28% year-on-year decrease in net profit for 2025, with projected revenue of 1.251 billion yuan, up 9.83% [34] - QiPai Technology's shareholder subscribed for 6.3 million shares, accounting for 5.49% of the total share capital [35] - Qilin Security's shareholders completed their planned share reductions without exceeding the original plan [36] Group 10 - Dameng Data announced the lifting of the detention of its senior vice president, allowing him to resume his duties [37] - Haiyou Engineering won a contract for the "NFPS COMP5" project worth approximately 4 billion USD, with the company's share exceeding 800 million USD [38] - Yatai Group plans to sell 20.81% of its shares in Northeast Securities, pending confirmation of financial statements [39]

| 序号 | 拟中选药品名称 | 适应症 | | --- | --- | --- | | 1 | 那屈肝素(那曲肝素)注 射剂 | 那屈肝素钙注射液主要用于治疗静脉血栓形成中度或高度 | | | | 危险的情况，预防静脉血栓栓塞性疾病；治疗已形成的深静 | | | | 脉血栓；联合阿司匹林用于不稳定性心绞痛和非 Q 波性心肌 | | | | 梗死急性期的治疗；在血液透析中预防体外循环中的血凝块 | | | | 形成。 | | 2 | 依诺肝素注射剂 | 依诺肝素钠注射液用于预防静脉血栓栓塞性疾病（预防静脉 | | | | 内血栓形成），特别是与骨科或普外手术有关的血栓形成； | | | | 治疗已形成的深静脉栓塞，伴或不伴有肺栓塞，临床症状不 | | | | 严重，不包括需要外科手术或溶栓剂治疗的肺栓塞；与阿司 | | | | 匹林合用，治疗不稳定性心绞痛及非 波心肌梗死；用于血 Q | | | | 液透析体外循环中，防止血栓形成。 | 河北常山生化药业股份有限公司 关于公司参与国家组织集采药品协议期满品种接续采购 证券代码：300255 证券简称：常山药业 公告编号：2026-6 拟中选的公告 本公司及董事 ...

| 序号 | 拟中选药品名称 | 适应症 | | --- | --- | --- | | 1 | 那屈肝素(那曲肝素)注 | 那屈肝素钙注射液主要用于治疗静脉血栓形成中度或高度 | | | | 危险的情况,预防静脉血栓栓塞性疾病;治疗已形成的深静 | | | 射剂 | 脉血栓;联合阿司匹林用于不稳定性心绞痛和非Q波性心肌 | | | | 梗死急性期的治疗;在血液透析中预防体外循环中的血凝块 | | | | 形成。 | | 2 | 依诺肝素注射剂 | 依诺肝素钠注射液用于预防静脉血栓栓塞性疾病(预防静脉 | | | | 内血栓形成),特别是与骨科或普外手术有关的血栓形成; | | | | 治疗已形成的深静脉栓塞,伴或不伴有肺栓塞,临床症状不 | | | | 严重,不包括需要外科手术或溶栓剂治疗的肺栓塞:与阿司 | | | | 匹林合用,治疗不稳定性心绞痛及非○波心肌梗死;用于血 | | | | 液透析体外循环中,防止血栓形成。 | | | | 12 12 | 格隆汇2月13日丨常山药业(300255.SZ)公布，公司于近日参加了国家组织集采药品协议期满品种接续采购办公室（简称接续采购 办公室）组织的国家组织集采 ...

格隆汇2月13日丨常山药业(300255.SZ)公布，公司于近日参加了国家组织集采药品协议期满品种接续采购办公室（简称接续采购 办公室）组织的国家组织集采药品协议期满品种接续采购的投标工作（简称本次接续采购），根据接续采购办公室发布的《国家 组织集采药品协议期满品种接续采购拟中选结果公示》，公司部分药品拟中选本次接续采购。 | 序号 | 拟中选药品名称 | 适应症 | | --- | --- | --- | | 1 | 那屈肝素(那曲肝素)注 | 那屈肝素钙注射液主要用于治疗静脉血栓形成中度或高度 | | | | 危险的情况,预防静脉血栓栓塞性疾病;治疗已形成的深静 | | | 射剂 | 脉血栓;联合阿司匹林用于不稳定性心绞痛和非Q波性心肌 | | | | 梗死急性期的治疗;在血液透析中预防体外循环中的血凝块 | | | | 形成。 | | 2 | 依诺肝素注射剂 | 依诺肝素钠注射液用于预防静脉血栓栓塞性疾病(预防静脉 | | | | 内血栓形成),特别是与骨科或普外手术有关的血栓形成; | | | | 治疗已形成的深静脉栓塞,伴或不伴有肺栓塞,临床症状不 | | | | 严重,不包括需要外科手术或溶栓剂治 ...